Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Compare
Compare
Traded in other countries / regions
VYGR.USAVYGR.MexicoVT6.Germany IPO Date
2015-11-18Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.38 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.94 | |||||
| Beneish M-Score | 21.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7 | |||||
| 3-Year EBITDA Growth Rate | 50.3 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year Book Growth Rate | 9.1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.01 | |||||
| 9-Day RSI | 37.48 | |||||
| 14-Day RSI | 40.74 | |||||
| 6-1 Month Momentum % | 28.35 | |||||
| 12-1 Month Momentum % | 19.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.96 | |||||
| Quick Ratio | 4.96 | |||||
| Cash Ratio | 3.58 | |||||
| Days Sales Outstanding | 40.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | -5.83 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 48.8 | |||||
| Net Margin % | 52.93 | |||||
| FCF Margin % | 30.23 | |||||
| ROE % | 74.55 | |||||
| ROA % | 45.41 | |||||
| ROIC % | 143.38 | |||||
| ROC (Joel Greenblatt) % | 315.18 | |||||
| ROCE % | 51.14 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.5 | |||||
| PE Ratio without NRI | 2.5 | |||||
| Price-to-Owner-Earnings | 5.89 | |||||
| PS Ratio | 1.36 | |||||
| PB Ratio | 1.41 | |||||
| Price-to-Tangible-Book | 1.41 | |||||
| Price-to-Free-Cash-Flow | 4.01 | |||||
| Price-to-Operating-Cash-Flow | 3.86 | |||||
| EV-to-EBIT | 1.64 | |||||
| EV-to-EBITDA | 1.59 | |||||
| EV-to-Forward-EBITDA | -2.28 | |||||
| EV-to-Revenue | 0.8 | |||||
| EV-to-Forward-Revenue | 3.06 | |||||
| EV-to-FCF | 2.69 | |||||
| Price-to-Projected-FCF | 9.9 | |||||
| Price-to-Graham-Number | 0.4 | |||||
| Price-to-Net-Current-Asset-Value | 1.63 | |||||
| Price-to-Net-Cash | 2.88 | |||||
| Earnings Yield (Greenblatt) % | 60.98 | |||||
| FCF Yield % | 18.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 231.936 | ||
| EPS (TTM) (€) | 2.813 | ||
| Beta | 0.62 | ||
| Volatility % | 95.14 | ||
| 14-Day RSI | 40.74 | ||
| 14-Day ATR (€) | 0.2996 | ||
| 20-Day SMA (€) | 8.0625 | ||
| 12-1 Month Momentum % | 19.85 | ||
| 52-Week Range (€) | 5.75 - 13.2 | ||
| Shares Outstanding (Mil) | 54.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Voyager Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(FRA:VT6)'s stock price today?
The current price of FRA:VT6 is €6.99. The 52 week high of FRA:VT6 is €13.20 and 52 week low is €5.75.
When is next earnings date of Voyager Therapeutics Inc(FRA:VT6)?
The next earnings date of Voyager Therapeutics Inc(FRA:VT6) is 2024-05-09 Est..
Does Voyager Therapeutics Inc(FRA:VT6) pay dividends? If so, how much?
Voyager Therapeutics Inc(FRA:VT6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers